| Literature DB >> 27428232 |
Azmal Kabir Sarker1, Hyung-Jun Im, Jin Chul Paeng, Gi Jeong Cheon, Keon Wook Kang, June-Key Chung, Dong Soo Lee.
Abstract
BACKGROUND: It has been known that plasmablastic lymphoma (PBL) is a neoplasm of immunocompromised patients occurring in soft tissue of oral cavity or in the vicinity whereas bone is an unlikely site to harbor PBL. However, its occurrence is increasingly being reported in immunocompetent individuals in either osseous or extra-oral sites. To our best knowledge, F-18 FDG PET/CT findings of PBL involving bones in an immunocompetent patient have not been reported, yet . CASEEntities:
Mesh:
Substances:
Year: 2016 PMID: 27428232 PMCID: PMC4956826 DOI: 10.1097/MD.0000000000004241
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.889
Figure 1X-ray skull: round-shaped osteolytic lesion in the right parieto temporal bone.
Figure 2MRI of PNS: soft tissue mass involving right mandibular ramus, angle, posterior part of body and surrounding masticator space, soft tissue mass involving right supero-posterior parieto temporal bone, diffuse infiltrative change in the subcutaneous spaces of the right neck and a few indeterminate lymph nodes in level II on the right side. MRI = magnetic resonance imaging, PNS = paranasal sinus.
Figure 3F-18 FDG PET/CT: hypermetabolic lesion on the right side of mandible, with sunburst appearance and increased FDG uptake along the periosteal reaction. Hypermetabolic lesions in the right parietal bone and right scapula. FDG = fluorodeoxyglucose, PET/CT = positron emission tomography/computed tomography.
Figure 4Tc-99m-MDP bone scan: increased tracer uptake in the mandible, right parietal bone, right scapula, and left 9th rib. MDP = methyl diphosphonate.